Atai Life Sciences Balance Sheet Health
Financial Health criteria checks 5/6
Atai Life Sciences has a total shareholder equity of $223.3M and total debt of $19.7M, which brings its debt-to-equity ratio to 8.8%. Its total assets and total liabilities are $269.1M and $45.9M respectively.
Key information
8.8%
Debt to equity ratio
US$19.66m
Debt
Interest coverage ratio | n/a |
Cash | US$106.25m |
Equity | US$223.26m |
Total liabilities | US$45.86m |
Total assets | US$269.12m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 9VC's short term assets ($131.4M) exceed its short term liabilities ($17.0M).
Long Term Liabilities: 9VC's short term assets ($131.4M) exceed its long term liabilities ($28.8M).
Debt to Equity History and Analysis
Debt Level: 9VC has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 9VC's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9VC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 9VC has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 39.5% each year.